Log in to search using one of your social media accounts:

 

HRT will not shorten lives, women told after new research published

Follow-up to alarming reports issued at turn of century says women on therapy do not die sooner than those on placebosWomen will be able to take hormone replacement pills without worrying that the therapy will shorten their lifespans, according to the longest follow-up yet of research that raised fears about the risks of a once-popular treatment.That earlier research was stopped early when unexpected harm was found to be caused by the use of hormone replacement therapy (HRT) – oestrogen alone or in combination with progestin, a synthetic hormone.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Menopause Medical research Health Cancer & wellbeing Society Science World news Source Type: news

Related Links:

This article is protected by copyright. All rights reserved.
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
Conclusions:The available literature suggests that HT is a viable option for the primary prevention of cardiovascular disease in postmenopausal women. Newer trials will likely verify this assessment. If this is enough to change clinical practice, however, remains to be seen given the general fear of HT by many with prescriptive authority, and also the women in our care. Objective: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this...
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
Publication date: February 2018 Source:Journal of Functional Foods, Volume 41 Author(s): Naice E.S. Monteiro, Lívia D. Queirós, Danielle B. Lopes, Adriana O. Pedro, Gabriela A. Macedo Menopause is a natural event that occurs in women around the age of 50 years, causing irregularities in the menstrual cycle until its complete end, due to the hormonal deficit, especially estrogen, that causes several unpleasant urogenital and vasomotor symptoms. Hormone replacement therapy has many benefits, but should be prescribed with caution in women with a history of stroke, thromboembolic events, certain types of cance...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Conclusions: Female sex hormones are important for the preservation of lung function in middle aged women. The accelerated lung function decline with menopause is likely caused by decreasing estrogen levels.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Epidemiology Source Type: research
Breast cancer is the most frequent cancer among women especially in the Western world where, despite improved survival, it is one of the leading causes of death (1). Furthermore, for several decades there has been an increase in incidence, though recently there seems to be a stabilization in risk or even a small decline in typical high-risk areas such as Europe and the USA but at the same time a steep increase in typical low-risk societies such as Japan (2). Breast cancer is often regarded as a singular disease, but recent discoveries are pointing to a variety of types of potentially different etiology. Thus, the female...
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Editorial Source Type: research
MN, 50 years old, BMI: 36. Menopause was 7 years ago. No hormone replacement therapy before. She was treated for breast cancer and stopped using tamoxifen two years ago. Asymptomatic. She underwent to a screening transvaginal ultrasound that showed an endometrial thickness of 0.6  cm. Diagnostic hysteroscopy visualized two endometrial polyps. Surgical hysteroscopy was performed with The Integrated Bigatti Shaver (IBS®). The IBS® consists in a 6° angle telescope with an integrated sheath and a working channel in which a rigid shaver system is inserted.
Source: The Journal of Minimally Invasive Gynecology - Category: OBGYN Authors: Source Type: research
CONCLUSION: Until additional studies are performed, the risks and benefits must be weighed on an individual basis with consideration of prophylaxis when a decision is made to continue these medications in the perioperative period. Part of this decision making includes the risk of fetal harm in an unwanted pregnancy in preparation for nonobstetric surgery versus an increased risk of venous thromboembolism. PMID: 28969534 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
(Natural News) Hormone replacement therapy is often touted for any number of things; these kinds of drugs are often given to women under the guise of reducing heart disease risk and minimizing the effects of menopause, for example. But are they really safe? While hormone replacement therapy (HRT) first gained popularity for reducing signs of...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
CONCLUSIONS: Fewer than half of all women received counseling and/or a prescription for HRT after diagnoses of iatrogenic menopause, and disparities were noted based on insurance status. These findings reflect a need for clearer guidelines on HRT during survivorship and improved efforts to reduce disparities in the distribution of survivorship care. PMID: 28923411 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Hormone Replacement Therapy | Hormones | Men | Menopause | Research | Science | Women